GleamWall
中文EN

ALMS ALUMIS INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1847367 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-72.6%
TTM EPS YoY-64.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-6,116.7%
Net margin-5,844.5%
FCF margin-4,433.3%
EBITDA margin-6,069.2%

Returns

ROE-110.9%
ROA-86.6%
ROIC (approx.)-109.3%
Asset turnover0.01x

Leverage & solvency

Liabilities / assets22.6%
Debt / equity0.00x
Current ratio5.57x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.76x
Accruals ratio-21.1%
Payout ratio—
Capex / revenue11.9%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$1.91M$1.66M$1.74M$1.93M$2.07M$2.67M$17.39M—
R&D expense$80.79M$85.34M$81.54M$82.78M$97.84M$108.75M$96.62M$87.20M
SG&A expense$20.19M$23.36M$18.61M$15.59M$19.52M$34.45M$22.30M$11.42M
Operating income-$99.08M-$148.85M-$98.41M-$96.44M-$115.29M-$140.54M-$101.53M-$98.62M
Pretax income-$94.88M-$143.98M—-$92.93M-$110.75M$50.76M—-$94.76M
Income tax$0-$1.76M—$0$0-$8.60M—$0
Net income-$94.88M-$142.22M-$93.05M-$92.93M-$110.75M$59.32M-$98.96M-$94.76M
EBITDA-$98.18M-$148.06M-$97.54M-$95.58M-$114.39M-$139.64M-$100.69M-$97.80M
EPS (basic)-0.73-1.11-0.74—-1.060.78-1.82—
EPS (diluted)-0.73-1.11-0.74—-1.060.77-1.82—
Weighted avg. shares (diluted)129.29M127.69M125.05M—104.11M76.64M65.44M—
Balance sheet
Cash & equivalents$57.69M$63.71M$63.88M$89.67M$65.26M$151.75M$128.54M$170.63M
Short-term investments———$218.83M$312.47M$334.57M$80.21M$118.74M
Current assets$442.59M$514.08M$532.41M$318.23M$393.29M$517.56M$225.53M$306.19M
PP&E, net$16.43M$16.85M$17.53M$18.19M$19.06M$20.33M$20.33M$20.97M
Total assets$488.71M$560.62M$671.59M$411.94M$488.01M$610.92M$261.30M$340.99M
Current liabilities$79.41M$76.23M$70.90M$73.32M$65.42M$85.58M$60.45M$50.91M
Total liabilities$110.29M$108.46M$104.57M$110.64M$103.24M$125.60M$92.98M$80.89M
Shareholders' equity$378.43M$452.16M$567.02M$301.30M$384.77M$485.33M$168.31M$260.10M
Cash flow statement
Operating cash flow-$79.57M-$81.50M-$87.08M-$71.91M-$110.91M-$106.35M-$80.36M-$74.76M
Capital expenditure$464,000$237,000$164,000$0$0$616,000$37,000$366,000
Free cash flow-$80.03M-$81.74M-$87.25M-$71.91M-$110.91M-$106.97M-$80.39M-$75.13M
Investing cash flow$65.94M$68.69M-$285.69M$95.01M$24.04M$129.40M$39.43M$30.95M
Financing cash flow$7.61M$12.63M$346.99M$1.32M$0——$5,000
Depreciation & amortization$900,000$800,000$871,000$867,000$900,000$900,000$843,000$820,000
Stock-based compensation$14.29M$14.27M$12.34M$8.11M$9.79M$18.64M$7.00M$6.36M
Share buybacks———$0$0——$0

Free plan shows the latest 8 periods; Pro shows all 15 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.